secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2025-08-20T23:59:59+00:00
Accession:  0001641172-25-024979
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Therapeutics reports Q2 2025 revenue $3.8M, operating loss $4.9M; acquired Sleep Center of Nevada
--------------------------------------------------------------------------------

- Q2 2025 revenue $3.8M vs $4.1M YoY; gross margin fell to 55% from 65%.
- Operating loss widened to $4.9M from $1.9M; expenses up 52% on acquisition-related costs.
- Cash at June 30, 2025 was $4.4M, down from $6.2M at December 31, 2024.
- Acquired Sleep Center of Nevada on June 10; generated ~$500k diagnostic revenue in 20 days with demand exceeding capacity.
- Entered management agreement with MISleep Solutions for Michigan center; opening expected October 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000164117225024979/0001641172-25-024979-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000164117225024979/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-024979

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer